ORAI3 silencing alters cell proliferation and cell cycle progression via c-myc pathway in breast cancer cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 3, 2013, Pages 752-760

  Faouzi, Malika ^a,b   Kischel, Philippe ^a   Hague, Frédéric ^a   Ahidouch, Ahmed ^a,c   Benzerdjeb, Nazim ^a,d   Sevestre, Henri ^a,d   Penner, Reinhold ^b   Ouadid Ahidouch, Halima ^a  

^a Université Picardie Jules Vernes   (France)

^b QUEEN S MEDICAL CENTER   (United States)

^c IBN ZOHR UNIVERSITY   (Morocco)

^d UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

Breast cancer; C myc pathway; Cell cycle; Cell proliferation; Orai3

Indexed keywords

CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL; MITOGEN ACTIVATED PROTEIN KINASE 1; MYC PROTEIN; ORAI CALCIUM RELEASE ACTIVATED CALCIUM MODULATOR 3; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; APOPTOSIS; BLOTTING, WESTERN; BREAST; BREAST NEOPLASMS; CALCIUM; CALCIUM CHANNELS; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOENZYME TECHNIQUES; MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-MYC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS;

EID: 84872463873     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.12.009     Document Type: Article

References (43)

1. Feske S., Gwack Y., Prakriya M., Srikanth S., Puppel S.-H., Tanasa B., Hogan P.G., Lewis R.S., Daly M., Rao A. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 2006, 441:179-185.
2. Shuttleworth T.J. Orai3 - the 'exceptional' Orai?. J. Physiol. 2012, 590:241-257.
3. Schindl R., Bergsmann J., Frischauf I., Derler I., Fahrner M., Muik M., Fritsch R., Groschner K., Romanin C. 2-Aminoethoxydiphenyl borate alters selectivity of Orai3 channels by increasing their pore size. J. Biol. Chem. 2008, 283:20261-20267.
4. Abdullaev I.F., Bisaillon J.M., Potier M., Gonzalez J.C., Motiani R.K., Trebak M. Stim1 and Orai1 mediate CRAC currents and store-operated calcium entry important for endothelial cell proliferation. Circ. Res. 2008, 103:1289-1299.
5. El Boustany C., Katsogiannou M., Delcourt P., Dewailly E., Prevarskaya N., Borowiec A.-S., Capiod T. Differential roles of STIM1, STIM2 and Orai1 in the control of cell proliferation and SOCE amplitude in HEK293 cells. Cell Calcium 2010, 47:350-359.
6. Bisaillon J.M., Motiani R.K., Gonzalez-Cobos J.C., Potier M., Halligan K.E., Alzawahra W.F., Barroso M., Singer H.A., Jourd'heuil D., Trebak M. Essential role for STIM1/Orai1-mediated calcium influx in PDGF-induced smooth muscle migration. Am. J. Physiol. Cell Physiol. 2010, 298:C993-C1005.
7. Yang S., Zhang J.J., Huang X.-Y. Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. Cancer Cell 2009, 15:124-134.
8. Motiani R.K., Abdullaev I.F., Trebak M. A novel native store-operated calcium channel encoded by Orai3: selective requirement of Orai3 versus Orai1 in estrogen receptor-positive versus estrogen receptor-negative breast cancer cells. J. Biol. Chem. 2010, 285:19173-19183.
9. Faouzi M., Hague F., Potier M., Ahidouch A., Sevestre H., Ouadid-Ahidouch H. Down-regulation of Orai3 arrests cell-cycle progression and induces apoptosis in breast cancer cells but not in normal breast epithelial cells. J. Cell. Physiol. 2011, 226:542-551.
10. Feske S. Calcium signalling in lymphocyte activation and disease. Nat. Rev. Immunol. 2007, 7:690-702.
11. Putney J.W. Capacitative calcium entry: from concept to molecules. Immunol. Rev. 2009, 231:10-22.
12. Pelengaris S., Khan M., Evan G. c-MYC: more than just a matter of life and death. Nat. Rev. Cancer 2002, 2:764-776.
13. Oster S.K., Ho C.S.W., Soucie E.L., Penn L.Z. The myc Oncogene: Marvelously Complex. Advances in Cancer Research 2002, volume 84:81-154. Academic Press.
14. Cross H.S., Hulla W., Tong W.-M., Peterlik M. Growth regulation of human colon adenocarcinoma-derived cells by calcium, vitamin D and epidermal growth factor. J. Nutr. 1995, 125:2004S-2008S.
15. Wierstra I., Alves J. The c-myc Promoter: Still MysterY and Challenge. Advances in Cancer Research 2008, volume 99:113-333. Academic Press. F.V.W. George, K. George (Eds.).
16. Köenig A., Linhart T., Schlengemann K., Reutlinger K., Wegele J., Adler G., Singh G., Hofmann L., Kunsch S., Büch T., Schäfer E., Gress T.M., Fernandez-Zapico M.E., Ellenrieder V. NFAT-induced histone acetylation relay switch promotes c-myc-dependent growth in pancreatic cancer cells. Gastroenterology 2010, 138:1189-1199.
17. Buchholz M., Schatz A., Wagner M., Michl P., Linhart T., Adler G., Gress T.M., Ellenrieder V. Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. EMBO J. 2006, 25:3714-3724.
18. Nilsson J.A., Cleveland J.L. Myc pathways provoking cell suicide and cancer. Oncogene 2003, 22:9007-9021.
19. Albihn A., Johnsen J.I., Arsenian Henriksson M. MYC in Oncogenesis and as a Target for Cancer Therapies. Advances in Cancer Research 2010, volume 107:163-224. Academic Press. F.V.W. George, K. George (Eds.).
20. Ponzielli R., Katz S., Barsyte-Lovejoy D., Penn L.Z. Cancer therapeutics: targeting the dark side of Myc. Eur. J. Cancer 2005, 41:2485-2501.
21. Liao D.J., Dickson R.B. c-Myc in breast cancer. Endocr. Relat. Cancer 2000, 7:143-164.
22. Berns E.M.J.J., Klijn J.G.M., van Putten W.L.J., van Staveren I.L., Portengen H., Foekens J.A. c-myc Amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res. 1992, 52:1107-1113.
23. Schlotter C., Vogt U., Bosse U., Mersch B., Wabetamann K. C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res. 2003, 5:R30-R36.
24. Watson P.H., Pon R.T., Shiu R.P.C. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res. 1991, 51:3996-4000.
25. Bergan R., Hakim F., Schwartz G., Kyle E., Cepada R., Szabo J., Fowler D., Gress R., Neckers L. Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging. Blood 1996, 88:731-741.
26. Schorl C., Sedivy J.M. Loss of protooncogene c-Myc function impedes G1 phase progression both before and after the restriction point. Mol. Biol. Cell 2003, 14:823-835.
27. Huang M.-J., Cheng Y.-c., Liu C.-R., Lin S., Liu H.E. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp. Hematol. 2006, 34:1480-1489.
28. Amati B., Alevizopoulos K., Vlach J. Myc and the cell cycle. Front. Biosci. 1998, 3:d250-d268.
29. Robertson D., Savage K., Reis-Filho J.S., Isacke C.M. Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue. BMC Cell Biol. 2008, 9:13.
30. Borowiec A.S., Hague F., Harir N., Guenin S., Guerineau F., Gouilleux F., Roudbaraki M., Lassoued K., Ouadid-Ahidouch H. IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation. J. Cell. Physiol. 2007, 212:690-701.
31. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
32. Grandori C., Cowley S.M., James L.P., Eisenman R.N. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol. 2000, 16:653-699.
33. Sears R., Leone G., DeGregori J., Nevins J.R. Ras enhances myc protein stability. Mol. Cell 1999, 3:169-179.
34. Turjanski A.G., Vaque J.P., Gutkind J.S. MAP kinases and the control of nuclear events. Oncogene 2007, 26:3240-3253.
35. Quesada I., Rovira J.M., Martin F., Roche E., Nadal A., Soria B. Nuclear KATP channels trigger nuclear Ca2+ transients that modulate nuclear function. Proc. Natl. Acad. Sci. 2002, 99:9544-9549.
36. Todorova M.G., Fuentes E., Soria B., Nadal A., Quesada I. Lysophosphatidic acid induces Ca2+ mobilization and c-Myc expression in mouse embryonic stem cells via the phospholipase C pathway. Cell. Signal. 2009, 21:523-528.
37. Dean M., Levine R.A., Ran W., Kindy M.S., Sonenshein G.E., Campisi J. Regulation of c-myc transcription and mRNA abundance by serum growth factors and cell contact. J. Biol. Chem. 1986, 261:9161-9166.
38. Szatkowski C., Parys J., Ouadid-Ahidouch H., Matifat F. Inositol 1,4,5-trisphosphate-induced Ca2+ signalling is involved in estradiol-induced breast cancer epithelial cell growth. Mol. Cancer 2010, 9:156.
39. Chang H.T., Hsu S.S., Chen J.S., Lin K.L., Wang J.L., Cheng H.H., Lu Y.C., Jiann B.P., Liu C.P., Huang J.K., Yeh J.H., Chiang A.J., Chen W.C., Jan C.R. Effect of diethylstilbestrol on Ca2+ handling and cell viability in human breast cancer cells. Chin. J. Physiol. 2003, 46:187-192.
40. R.K. Motiani, X. Zhang, K.E. Harmon, R.S. Keller, K. Matrougui, J.A. Bennett, M. Trebak, Orai3 is an estrogen receptor α-regulated Ca2+ channel that promotes tumorigenesis, FASEB J. (in press), (September 19, 2012). http://dx.doi.org/10.1096/fj.12-213801.
41. Monteith G.R., McAndrew D., Faddy H.M., Roberts-Thomson S.J. Calcium and cancer: targeting Ca2+ transport. Nat. Rev. Cancer 2007, 7:519-530.
42. Pla A.F., Avanzato D., Munaron L., Ambudkar I.S. Ion channels and transporters in cancer. 6. Vascularizing the tumor: TRP channels as molecular targets. Am. J. Physiol. Cell Physiol. 2012, 302:C9-C15.
43. Wulff H., Castle N.A., Pardo L.A. Voltage-gated potassium channels as therapeutic targets. Nat. Rev. Drug Discov. 2009, 8:982-1001.